Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeting N-Terminal Pro-Brain Natriuretic Peptide in Older Versus Younger Acute Decompensated Heart Failure Patients.
Stienen S, Salah K, Eurlings LW, Bettencourt P, Pimenta JM, Metra M, Bayes-Genis A, Verdiani V, Bettari L, Lazzarini V, Tijssen JP, Pinto YM, Kok WE. Stienen S, et al. Among authors: tijssen jp. JACC Heart Fail. 2016 Sep;4(9):736-45. doi: 10.1016/j.jchf.2016.05.007. Epub 2016 Jul 6. JACC Heart Fail. 2016. PMID: 27395353 Free article.
N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) Measurements Until a 30% Reduction Is Attained During Acute Decompensated Heart Failure Admissions and Comparison With Discharge NT-proBNP Levels: Implications for In-Hospital Guidance of Treatment.
Stienen S, Salah K, Dickhoff C, Carubelli V, Metra M, Magrini L, Di Somma S, Tijssen JP, Pinto YM, Kok WE. Stienen S, et al. Among authors: tijssen jp. J Card Fail. 2015 Nov;21(11):930-4. doi: 10.1016/j.cardfail.2015.07.011. Epub 2015 Jul 26. J Card Fail. 2015. PMID: 26216495 Free article.
Challenging the two concepts in determining the appropriate pre-discharge N-terminal pro-brain natriuretic peptide treatment target in acute decompensated heart failure patients: absolute or relative discharge levels?
Stienen S, Salah K, Eurlings LW, Bettencourt P, Pimenta JM, Metra M, Bayes-Genis A, Verdiani V, Bettari L, Lazzarini V, Tijssen JP, Pinto YM, Kok WE. Stienen S, et al. Among authors: tijssen jp. Eur J Heart Fail. 2015 Sep;17(9):936-44. doi: 10.1002/ejhf.320. Epub 2015 Jul 29. Eur J Heart Fail. 2015. PMID: 26222618 Free article.
Evaluation of ketanserin in the prevention of restenosis after percutaneous transluminal coronary angioplasty. A multicenter randomized double-blind placebo-controlled trial.
Serruys PW, Klein W, Tijssen JP, Rutsch W, Heyndrickx GR, Emanuelsson H, Ball SG, Decoster O, Schroeder E, Liberman H, et al. Serruys PW, et al. Among authors: tijssen jp. Circulation. 1993 Oct;88(4 Pt 1):1588-601. doi: 10.1161/01.cir.88.4.1588. Circulation. 1993. PMID: 8403306 Clinical Trial.
Dutch outcome in implantable cardioverter-defibrillator therapy (DO-IT): registry design and baseline characteristics of a prospective observational cohort study to predict appropriate indication for implantable cardioverter-defibrillator.
van Barreveld M, Dijkgraaf MGW, Hulleman M, Boersma LVA, Delnoy PPHM, Meine M, Tuinenburg AE, Theuns DAMJ, van der Voort PH, Kimman GP, Buskens E, Tijssen JPG, Bruinsma N, Verstraelen TE, Zwinderman AH, van Dessel PHFM, Wilde AAM; DO-IT investigators. van Barreveld M, et al. Among authors: tijssen jpg. Neth Heart J. 2017 Oct;25(10):574-580. doi: 10.1007/s12471-017-1016-x. Neth Heart J. 2017. PMID: 28785868 Free PMC article.
15 results